These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 23035244)
1. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244 [TBL] [Abstract][Full Text] [Related]
2. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Toledo F; Wahl GM Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450 [TBL] [Abstract][Full Text] [Related]
4. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy. Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458 [TBL] [Abstract][Full Text] [Related]
5. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276 [TBL] [Abstract][Full Text] [Related]
6. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333 [TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Li Q; Lozano G Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034 [TBL] [Abstract][Full Text] [Related]
8. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179 [TBL] [Abstract][Full Text] [Related]
9. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4. Fan C; Wang X Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445 [TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Palani CD; Beck JF; Sonnemann J Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection. Yang H; Zheng Z; Zhao LY; Li Q; Liao D Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167 [TBL] [Abstract][Full Text] [Related]
13. Mouse models of Mdm2 and Mdm4 and their clinical implications. Xiong S Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795 [TBL] [Abstract][Full Text] [Related]
14. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill. Xie X; He G; Siddik ZH Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580 [TBL] [Abstract][Full Text] [Related]
15. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Swetzig WM; Wang J; Das GM Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605 [TBL] [Abstract][Full Text] [Related]
17. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
18. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Qi DL; Cobrinik D Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758 [TBL] [Abstract][Full Text] [Related]
19. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744 [TBL] [Abstract][Full Text] [Related]